Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2022-03-01 Director's Dealing
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2022-03-01 English
SC 13G/A
Major Shareholding Notification
2022-02-14 English
SC 13G/A
Major Shareholding Notification
2022-02-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate updates. The text includes references to Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), indicating an update on preliminary financial information and a corporate presentation for an investor conference. The document does not contain full financial statements or detailed financial analysis but rather a brief update and a presentation attachment. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not qualify as a full Annual Report, Interim Report, Earnings Release, or Investor Presentation by itself. The document length is about 5,010 characters, which is relatively short and consistent with a Form 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-01-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a press release about the FDA removing a clinical hold on a trial, which is attached as an exhibit. The document is short (3654 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-12-09 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-12-03 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.